Scarica l'app Stockscreener
0.5486
0.25%
-0.0014
Pre-mercato:
.55
0.0014
+0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.55
Aprire:
$0.5475
Volume 24 ore:
1.13M
Relative Volume:
0.62
Capitalizzazione di mercato:
$30.29M
Reddito:
$30.99M
Utile/perdita netta:
$-141.41M
Rapporto P/E:
-0.2086
EPS:
-2.63
Flusso di cassa netto:
$-118.12M
1 W Prestazione:
+1.48%
1M Prestazione:
+2.81%
6M Prestazione:
-52.30%
1 anno Prestazione:
-94.51%
Intervallo 1D:
$0.5461
$0.55
Intervallo di 1 settimana:
$0.54
$0.55
Portata 52W:
$0.2202
$10.50
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Nome
Marinus Pharmaceuticals Inc
Settore
Industria
Telefono
484-801-4670
Indirizzo
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Confronta MRNS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.5486 | 30.29M | 30.99M | -141.41M | -118.12M | -2.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-23 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-08-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-04-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-04-15 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-01-20 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-09-30 | Iniziato | Truist | Buy |
| 2020-07-01 | Iniziato | Cowen | Outperform |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-09 | Iniziato | Craig Hallum | Buy |
| 2019-12-20 | Iniziato | Oppenheimer | Outperform |
| 2019-03-05 | Ripresa | Jefferies | Buy |
| 2019-02-27 | Downgrade | Mizuho | Buy → Neutral |
| 2019-02-06 | Iniziato | Leerink Partners | Outperform |
| 2018-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-03-20 | Iniziato | Mizuho | Buy |
| 2018-02-15 | Iniziato | H.C. Wainwright | Buy |
| 2017-12-14 | Iniziato | Laidlaw | Buy |
| 2016-08-10 | Reiterato | Jefferies | Buy |
| 2016-06-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-03-08 | Reiterato | Stifel | Buy |
| 2015-12-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2015-11-17 | Iniziato | Jefferies | Buy |
| 2015-10-30 | Reiterato | Oppenheimer | Outperform |
| 2015-08-05 | Reiterato | Oppenheimer | Outperform |
Mostra tutto
Marinus Pharmaceuticals Inc Borsa (MRNS) Ultime notizie
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Morgan Stanley's Strategic Acquisition of Marinus Pharmaceuticals Shares - GuruFocus.com
Vanguard Group Inc Reduces Holdings in Marinus Pharmaceuticals I - GuruFocus.com
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals director sells shares worth $869 - MSN
UPCOMING MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus pharmaceuticals director sells shares for $864 - MSN
Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis - MarketBeat
Marinus pharmaceuticals director sells shares for $864 By Investing.com - Investing.com Canada
Immedica to buy Marinus Pharmaceuticals for $151m - MSN
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene - Barchart
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, - openPR
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AE, MRNS, SASR, ROIC to Take Action - The Malaysian Reserve
Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints - MSN
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know - MSN
Beryl Capital Management LLC Acquires Significant Stake in Marin - GuruFocus.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Marinus Pharmaceuticals, Inc.MRNS - Kilgore News Herald
Immedica Pharma AB’s Acquisition of Marinus Pharmaceuticals - Global Legal Chronicle
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc.MRNS - Business Wire
Immedica acquires Marinus in $151 million deal - The Pharma Letter
Marinus Therapeutics in Radnor Acquired by Swedish Company - MSN
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders - Marketscreener.com
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - Citeline News & Insights
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – VINC, VCSA, MRNS, MHLD - GlobeNewswire Inc.
Marinus executives in line for bonuses after acquisition deal triggers retention payouts - The Business Journals
After phase 3 setbacks, troubled Marinus inks $151M sale to Immedica Pharma - FiercePharma
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the MergerVINC, VCSA, MRNS, MHLD - Stockhouse Publishing
Neutral rating reaffirmed for Marinus stock as acquisition deal closure nears - Investing.com Canada
Marinus Pharmaceuticals to be acquired by Immedica for 55c per share - Yahoo Finance
Immedica Pharma AB entered into definitive agreement to acquire Marinus Pharmaceuticals, Inc.. - Marketscreener.com
Orion and Marinus Terminate Agreement for ganaxolone in Europe - Marketscreener.com
Immedica to buy rare disease drugmaker Marinus for $151 million - Crain's Chicago Business
Immedica to acquire Marinus Pharmaceuticals for $151 million By Investing.com - Investing.com Canada
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com
Marinus Pharmaceuticals ends agreements with Orion Corporation By Investing.com - Investing.com Nigeria
Marinus Pharmaceuticals ends agreements with Orion Corporation - Investing.com India
Immedica Pharma AB entered into an agreement to acquire Marinus Pharmaceuticals, Inc.. - Marketscreener.com
Immedica to Acquire Marinus Pharmaceuticals in $151 Million Deal; Shares Surge 43% - GuruFocus.com
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40% - Benzinga
Marinus Pharmaceuticals Inc Azioni (MRNS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.82%
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):